By using siRNA to inhibit FXI at mRNA level, the effect of the drug can immediately be reversed at need using replacement therapy with fresh frozen plasma, which is an accepted method in clinical practice for the normalization of FXI levels in hemophilia C patients.28 This evidence concerns the gene F11 and congenital factor XI deficiency.